2025-07-21
In recent years, significant progress has been made in gene therapy for genetic diseases. In particular, the ex - vivo gene therapy strategy based on lentiviral vectors has been successfully applied to diseases such as severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA - SCID). However, existing therapies still face challenges such as high toxic side effects of chemotherapy pre - treatment, complex operations, and high costs, and have limited efficacy for diseases involving multiple tissues.
2025-07-21
Recently, led by the Center for Excellence in Brain Science and Intelligence Technology of the Chinese Academy of Sciences, in collaboration with top domestic research institutions such as the Suzhou Institute of Brain - like Intelligence, Huazhong University of Science and Technology, and the BGI Life Sciences Research Institute, and in cooperation with scientific teams from countries like France, Sweden, and the UK, a significant breakthrough has been made in brain science research.
2025-07-11
A Russian research team has recently published a groundbreaking achievement. By combining density functional theory (DFT) calculations with experimental verification, they successfully uncovered the molecular mechanism of sucrose molecules in cryopreservation, presenting a brand - new strategy for optimizing the freeze - drying process of biological samples and for biological cryopreservation. This research not only resolves the long - standing problem of ice - crystal damage that has troubled cryobiology but also initiates an interdisciplinary research paradigm of "theoretical calculations guiding experimental design".
2025-07-11
An international research team composed of four top - tier institutions, namely Cincinnati Children's Hospital, Icahn School of Medicine at Mount Sinai, Tokyo Institute of Science, and Takeda Pharmaceutical Company, has achieved a revolutionary breakthrough in the field of organoid technology. The team published their latest research findings in Nature Biomedical Engineering, successfully cultivating liver organoids with a functional vascular network, which paves a new way for the treatment of hemophilia and liver regenerative medicine.
2025-07-03
On June 25, 2025, the team led by Professor Wang Huiying and Dr. Jin Bo from Shenzhen Hospital of Beijing University of Chinese Medicine collaborated with Shandong Yinfeng Life Science Research Institute to develop the "ovarian dual activation" technology. Through this technology, patients with POI (primary ovarian insufficiency) underwent intra - operative freeze - thaw activation of ovarian tissue. After intra - operative transplantation, a baby was born, and both the mother and the baby are healthy and safe.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
